We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

92 hedge funds and large institutions have $792M invested in Portola Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 10

217% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 12

46% more capital invested

Capital invested by funds: $542M → $792M (+$250M)

33% more funds holding

Funds holding: 6992 (+23)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

Holders
92
Holders Change
+23
Holders Change %
+33.33%
% of All Funds
2.67%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
33
Increased
38
Reduced
12
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
26
Wells Fargo
California
$4.96M +$2.69M +110,808 +135%
Adage Capital Partners
27
Adage Capital Partners
Massachusetts
$4.7M +$4.44M +182,685 New
BIT
28
BlackRock Institutional Trust
California
$4.62M -$398K -16,373 -8%
EAM
29
Eventide Asset Management
Massachusetts
$4.46M +$4.21M +173,300 New
NI
30
Numeric Investors
Massachusetts
$4.19M +$3.96M +162,822 New
State Street
31
State Street
Massachusetts
$4.17M +$950K +39,086 +32%
BIM
32
Bogle Investment Management
Massachusetts
$3.82M +$3.61M +148,483 New
Northern Trust
33
Northern Trust
Illinois
$3.71M +$439K +18,057 +14%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.55M +$1.39M +57,116 +136%
Norges Bank
35
Norges Bank
Norway
$2.38M
Morgan Stanley
36
Morgan Stanley
New York
$2.03M +$315K +12,982 +20%
LCM
37
Laurion Capital Management
New York
$1.96M +$1.85M +76,100 New
CAM
38
Cormorant Asset Management
Massachusetts
$1.93M +$1.82M +75,000 New
TCIM
39
TIAA CREF Investment Management
New York
$1.93M +$743K +30,560 +69%
BA
40
BlackRock Advisors
Delaware
$1.87M +$1.02M +42,074 +138%
MSA
41
Mason Street Advisors
Wisconsin
$1.76M +$1.66M +68,500 New
SFM
42
Sphera Funds Management
Israel
$1.63M +$1.54M +63,471 New
Macquarie Group
43
Macquarie Group
Australia
$1.38M +$1.3M +53,683 New
PAMU
44
Pictet Asset Management (UK)
United Kingdom
$1.34M +$129K +5,300 +11%
Geode Capital Management
45
Geode Capital Management
Massachusetts
$1.22M +$54.1K +2,225 +5%
HCM
46
Harvey Capital Management
Florida
$1.12M +$1.05M +43,400 New
GF
47
Gerry Farber
New York
$1.03M +$972K +40,000 New
NTCOC
48
Northern Trust Company of Connecticut
Connecticut
$934K +$882K +36,282 New
Goldman Sachs
49
Goldman Sachs
New York
$897K -$4.36M -179,399 -84%
TC
50
TFS Capital
Pennsylvania
$888K +$35K +1,440 +4%

PTLA Hedge Fund Activity: Q4 2013 in Review

92 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2013, worth a combined $792M — up 46% from $542M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PTLA positions and 10 closed out — a net gain of 23 holders — while 38 added to existing stakes and 12 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $118M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $43.4M.

  • 92 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2013, up from 69 in Q3 2013.
  • Funds reported $792M of Portola Pharmaceuticals, Inc. stock for Q4 2013, up 46% quarter-over-quarter.
  • 33 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2013 and 10 closed out, a net change of +23 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q4 2013 was Wellington Management Group, an estimated $118M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q4 2013 was Bain Capital Public Equity Management, an estimated $43.4M sold.

Based on aggregated 13F filings for Q4 2013.